VeriTeQ Awarded New U.S. Patent for Wireless Molecular Sensor System and Process

Patent to be used in development of bio-sensing microchip applications

DELRAY BEACH, FL – May 21, 2015 –VeriTeQ Corporation (“VeriTeQ” or the “Company”) (OTC Markets: VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has been awarded a U.S. Patent for Wireless Molecular Sensor System and Process.  The Company intends to utilize the patent in the development of future bio-sensing microchip applications, initially focused on its radiation dose measurement technologies used during cancer treatment.

This newest patent covers methods and systems for measuring and wirelessly communicating particular molecular levels using an implantable sensor device operable without the use of batteries. These implantable biosensor systems use radio frequency technology to wirelessly transmit information between a transponder passively powered on a chip and a remote transponder. Information transmitted via this wireless communication system quantifies a physiological metric with respect to the levels of specific molecules measured by the biosensor. 

The Company plans to apply this patent in conjunction with its future radiation dose measurement products, to be used during cancer treatment therapies. Within its broad intellectual property portfolio, the Company has an existing patent for implantable sensors that dynamically monitor multiple biological and physiological parameters, such as temperature to monitor hyperthermia.  

“VeriTeQ has a robust intellectual property portfolio and we believe this latest patent award, which is broad in scope, further strengthens our position to develop in vivo bio-sensing applications for patient monitoring and treatment,” stated Scott R. Silverman, Chairman and CEO of VeriTeQ. “Although not currently marketed, our radiation dose measurement technologies, which are FDA cleared and were previously commercialized, can be ramped up and made available to patients once again with the necessary capital in place.” 

About VeriTeQ

VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.

Statements in this press release that are not purely historical facts, including statements about our beliefs, intentions or future expectations, may be"forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements consist of any statement other than a recitation of historical fact and can be identified by the use of forward-looking terminology such as “may”, “expect”, “anticipate”,“intend”, “estimate” or the negative thereof or other variations thereof or comparable terminology. The reader is cautioned that all forward looking statements involve risks and uncertainties and are subject to change at any time, and that our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ’s ability to continue to raise capital to fund its operations; VeriTeQ’s ability to successfully commercialize its Q Inside Safety Technology; as well as other risks or events beyond VeriTeQ’s control. Additional information about these and other factors may be described in VeriTeQ’s Form 10-K, filed on April 14, 2015. VeriTeQ undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

More than 10,000 Women Have Received Motiva Breast Implants with VeriTeQ’s Q Inside Safety Technology

Adoption of Q Inside Safety Technology Continues to Expand Across the Globe

DELRAY BEACH, FL – June 2, 2015 –VeriTeQ Corporation (“VeriTeQ” or the “Company”) (OTC Markets: VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that more than 10,000 women have now received Motiva Implant Matrix® breast implants, manufactured by Establishment Labs S.A. (“EL”), with VeriTeQ’s Q Inside Safety Technology™. 

VeriTeQ’s FDA cleared Q Inside Safety Technology™ acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer. Q Inside Safety Technology™ may also provide an extra level of protection to the patient in the event of a recall or other safety event.

"This is further proof that women seeking breast augmentation demand the highest safety profile for this procedure and as a result are increasingly choosing Motiva breast implants with Q Inside Safety Technology,” said Juan Jose Chacon-Quiros, CEO of EL.

Scott R. Silverman, Chairman and Chief Executive Officer of VeriTeQ, stated, “Better technology means better products, and the combination of EL’s advanced breast implants with our Q Inside Safety Technology is transforming the global aesthetics industry to provide a best-in-class product for the ultimate in patient safety and device quality. The adoption we are seeing among patients and physicians is a testament to that.” 

EL’s Motiva Implant Matrix® Ergonomix™, VelvetSurface® PLUS, and SilkSurface® PLUS, all with VeriTeQ’s Q Inside Safety Technology, have received CE Mark approval.

About VeriTeQ

VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.

About EL

Establishment Labs is a global privately held breast, body and facial aesthetic company, with offices in Florida, Costa Rica and Belgium, that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast (www.motivaimplants.com) and body shaping implants.  Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implant Matrix® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC. For more information on EL, please visit www.establishmentlabs.com. 

Statements in this press release that are not purely historical facts, including statements about our beliefs, intentions or future expectations, may be"forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements consist of any statement other than a recitation of historical fact and can be identified by the use of forward-looking terminology such as “may”, “expect”, “anticipate”, “intend”, “estimate” or the negative thereof or other variations thereof or comparable terminology. The reader is cautioned that all forward looking statements involve risks and uncertainties and are subject to change at any time, and that our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ’s ability to continue to raise capital to fund its operations; VeriTeQ’s ability to successfully commercialize its Q Inside Safety Technology; as well as other risks or events beyond VeriTeQ’s control. Additional information about these and other factors may be described in VeriTeQ’s Form 10-K, filed on April 14, 2015. VeriTeQ undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact:

VeriTeQ

Allison Tomek, 561-846-7003

atomek@veriteqcorp.com

VeriTeQ Corporation Announces Reverse Stock Split

Company to trade as VTEQD for 20 trading days

DELRAY BEACH, FL – July 28, 2015 – VeriTeQ Corporation (OTC Markets: VTEQ) (“VeriTeQ” or the “Company”), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that its Board of Directors and FINRA have approved a reverse split of the Company’s common stock at a ratio of 1-for-10,000, commencing at the open of trading on July 29, 2015. 

The Company’s ticker symbol will be VTEQD for 20 trading days to designate that it is trading on a post-reverse split basis. VeriTeQ’s post-split common stock will trade under the new CUSIP Number 923449 300. As a result of the reverse stock split, each 10,000 pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of the respective holders, and the number of outstanding common shares will be reduced from approximately 4.4 billion shares to approximately 446,000 shares. The reverse stock split will also apply to common stock issuable upon the conversion of outstanding notes payable and convertible preferred stock, and upon the exercise of outstanding warrants and stock options. 

The Company's transfer agent, VStock Transfer, LLC, will provide instructions to stockholders regarding the process for exchanging shares. No fractional shares will be issued as a result of the reverse stock split, and stockholders who otherwise would be entitled to a fractional share will receive, in lieu thereof, a cash payment which will equal the product obtained by multiplying (a) the fraction to which the stockholder would otherwise be entitled; by (b) the per share closing sales price of the Company’s common stock on the effective date of the reverse stock split. 

The reverse stock split was previously approved by the Company’s Board of Directors and ratified by the Company’s stockholders on May 26, 2015. Further details of the reverse stock split are contained in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission this day. 

About VeriTeQ
VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microtransponder technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com. 

Statements in this press release that are not purely historical facts, including statements about our beliefs, intentions or future expectations, may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements consist of any statement other than a recitation of historical fact and can be identified by the use of forward-looking terminology such as “may,” “expect,” “anticipate,” “intend,” “estimate,” or the negative thereof or other variations thereof or comparable terminology. The reader is cautioned that all forward looking statements involve risks and uncertainties and are subject to change at any time, and that our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ’s ability to continue to raise capital to fund its operations; VeriTeQ’s ability to successfully commercialize its Q Inside Safety Technology; as well as other risks or events beyond VeriTeQ’s control. Additional information about these and other factors may be described in VeriTeQ’s Form 10-K, filed on April 14, 2015. VeriTeQ undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law. 

Contact: 
VeriTeQ
Allison Tomek, 561-846-7003
atomek@veriteqcorp.com 

RECENT FDA DRAFT GUIDANCE NAMES RFID AS A TECHNOLOGY SOLUTION FOR DIRECT PART MARKING

VeriTeQ’s Q Inside Safety Technology meets the direct part marking requirement of the FDA’s final rule as an RFID microtransponder for unique device identification

DELRAY BEACH, FL – July 29, 2015 – VeriTeQ Corporation (“VeriTeQ” or the “Company”) (OTC Markets: VTEQD), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that the Food and Drug Administration (the “FDA”) has released draft guidance that names radio frequency identification (“RFID”) as a technology solution to comply with the direct part marking requirements of the FDA’s final rule for unique device identification of medical devices. VeriTeQ’s Q Inside Safety Technology™ is an FDA cleared implantable RFID microtransponder that can be used to identify implantable and reusable/reprocessable medical devices. 

In 2013, the FDA released a final rule requiring a unique device identification system designed to adequately identify medical devices through distribution and use. In most cases, the final rule requires a unique device identifier (“UDI”) to be included on device labels and packages. In addition, the final rule states that a device that must bear a UDI on its label must also bear a permanent marking providing the UDI on the device itself if the device is intended to be used more than once and intended to be reprocessed before each use. Although subject to change, the recent 2015 draft guidance states that acceptable methods to directly mark a device with a UDI include affixing a permanent tag such as an RFID tag to the device. 

VeriTeQ’s FDA cleared Q Inside Safety Technology acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients with access to secure online databases to retrieve device-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer. Q Inside Safety Technology may also provide an extra level of protection to the patient in the event of a recall or other safety event. 

Scott R. Silverman, Chairman and Chief Executive Officer of VeriTeQ, stated, “We are currently working with some of the leading breast implant manufacturers to help them understand that Q Inside Safety Technology not only helps them meet the FDA’s requirement for direct part marking of breast implant sizers and other reusable/reprocessable medical devices, but also offers added value through its ability to help provide long-term outcome data and other healthcare analytics. We also believe that our Q Inside Safety Technology can provide similar benefits to other medical device makers, including manufacturers of artificial joints and vascular ports.” 

About VeriTeQ
VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com. 

Statements in this press release that are not purely historical facts, including statements about our beliefs, intentions or future expectations, may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements consist of any statement other than a recitation of historical fact and can be identified by the use of forward-looking terminology such as “may”, “expect”, “anticipate”, “intend”, “estimate” or the negative thereof or other variations thereof or comparable terminology. The reader is cautioned that all forward looking statements involve risks and uncertainties and are subject to change at any time, and that our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ’s ability to continue to raise capital to fund its operations; VeriTeQ’s ability to successfully commercialize its Q Inside Safety Technology; as well as other risks or events beyond VeriTeQ’s control. Additional information about these and other factors may be described in VeriTeQ’s Form 10-K, filed on April 14, 2015. VeriTeQ undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law. 

Contact: 
VeriTeQ
Allison Tomek, 561-846-7003
atomek@veriteqcorp.com

VERITEQ CORPORATION RETAINS DR. MICHAEL FIORILLO AS A CONSULTANT

 

Highly regarded plastic surgeon to help VeriTeQ increase awareness of Q Inside Safety Technology among patients and device manufacturers and leverage customer relationships

DELRAY BEACH, FL – August 3, 2015 – VeriTeQ Corporation (“VeriTeQ” or the “Company”) (OTC Markets: VTEQD), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has retained prominent plastic surgeon Dr. Michael A. Fiorillo as a consultant to the Company. 

Dr. Fiorillo is a double board certified plastic and cosmetic surgeon renowned worldwide as an authority in the field. He is a distinguished author with numerous publications on plastic surgery, including peer-reviewed medical articles, books, and textbooks. Highly respected by his patients and the plastic surgery community, Dr. Fiorillo’s expertise has won him the trust of the thousands of patients that have attended his practices in New York and New Jersey since 1998. His expertise and thousands of successful surgeries have brought him the honor of being appointed by Sientra, one of only three FDA cleared breast implant marketers in the U.S., to train other doctors in the United States. 

“Q Inside Safety Technology can offer significant benefits to the plastic surgery industry, and I am pleased to assist VeriTeQ with its mission of improving patient safety and ensuring device quality,” stated Dr. Fiorillo. 

Scott R. Silverman, Chairman and Chief Executive Officer of VeriTeQ, stated, “We have a strong relationship with Dr. Fiorillo, an expert in the medical aesthetic industry, which we believe can help us increase awareness of the benefits offered by our Q Inside Safety Technology™ among medical device manufacturers, physicians and patients.” 

VeriTeQ’s FDA cleared Q Inside Safety Technology™ acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients with access to secure online databases to retrieve device-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer. Q Inside Safety Technology™ may also provide an extra level of protection to the patient in the event of a recall or other safety event. 

About VeriTeQ
VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com. 

Statements in this press release that are not purely historical facts, including statements about our beliefs, intentions or future expectations, may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements consist of any statement other than a recitation of historical fact and can be identified by the use of forward-looking terminology such as “may”, “expect”, “anticipate”, “intend”, “estimate” or the negative thereof or other variations thereof or comparable terminology. The reader is cautioned that all forward looking statements involve risks and uncertainties and are subject to change at any time, and that our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ’s ability to continue to raise capital to fund its operations; VeriTeQ’s ability to successfully commercialize its Q Inside Safety Technology; as well as other risks or events beyond VeriTeQ’s control. Additional information about these and other factors may be described in VeriTeQ’s Form 10-K, filed on April 14, 2015. VeriTeQ undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law. 

Contact: 
VeriTeQ
Allison Tomek, 561-846-7003
atomek@veriteqcorp.com

VERITEQ SHIPS 33,000 UNITS OF Q INSIDE SAFETY TECHNOLOGY YEAR-TO-DATE TO ESTABLISHMENT LABS

DELRAY BEACH, FL – August 5, 2015 – VeriTeQ Corporation (“VeriTeQ” or the “Company”) (OTC Markets: VTEQD), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has shipped 33,000 units of its Q Inside Safety Technology™ year-to-date to breast implant manufacturer Establishment Labs, S. A. (“EL”). 

VeriTeQ’s FDA cleared Q Inside Safety Technology acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients with access to secure online databases to retrieve device-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer. Q Inside Safety Technology may also provide an extra level of protection to the patient in the event of a recall or other safety event. 

EL markets multiple options within their line of best-of-breed breast implants under the Motiva Implant Matrix® brand name throughout Europe, the United Kingdom, Latin America and Asia. EL’s Motiva Implant Matrix® Ergonomix™, VelvetSurface® PLUS, and SilkSurface® PLUS, all with VeriTeQ’s Q Inside Safety Technology, have received CE Mark approval. 

Scott R. Silverman, Chairman and Chief Executive Officer of VeriTeQ, stated, “As EL continues to increase its production of Motiva Implant Matrix breast implants with Q Inside Safety Technology, we continue to see increased orders, and therefore increased revenue, for our product. EL is making a significant impact in the medical aesthetics industry and we believe their growth trend will continue.” 

About VeriTeQ
VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com. 

About EL
Establishment Labs is a global privately held breast, body and facial aesthetic company, with offices in Florida, Costa Rica and Belgium, that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast (www.motivaimplants.com) and body shaping implants. Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implant Matrix® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC. For more information on EL, please visit www.establishmentlabs.com. 

Statements in this press release that are not purely historical facts, including statements about our beliefs, intentions or future expectations, may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements consist of any statement other than a recitation of historical fact and can be identified by the use of forward-looking terminology such as “may”, “expect”, “anticipate”, “intend”, “estimate” or the negative thereof or other variations thereof or comparable terminology. The reader is cautioned that all forward looking statements involve risks and uncertainties and are subject to change at any time, and that our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ’s ability to continue to raise capital to fund its operations; VeriTeQ’s ability to successfully commercialize its Q Inside Safety Technology; as well as other risks or events beyond VeriTeQ’s control. Additional information about these and other factors may be described in VeriTeQ’s Form 10-K, filed on April 14, 2015. VeriTeQ undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law. 

Contact: 
VeriTeQ
Allison Tomek, 561-846-7003
atomek@veriteqcorp.com